Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8701 |
High Similarity |
NPD6234 |
Discontinued |
0.8693 |
High Similarity |
NPD4966 |
Approved |
0.8693 |
High Similarity |
NPD4965 |
Approved |
0.8693 |
High Similarity |
NPD4967 |
Phase 2 |
0.8618 |
High Similarity |
NPD37 |
Approved |
0.8323 |
Intermediate Similarity |
NPD7228 |
Approved |
0.8182 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8125 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.8025 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7986 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7947 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7917 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7904 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7891 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7891 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7877 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7862 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7808 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7765 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7744 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7742 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7727 |
Intermediate Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.7711 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7671 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7671 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7658 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7651 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7651 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7622 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7619 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7609 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7595 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7517 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7517 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7517 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7514 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7483 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7456 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7448 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7444 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7423 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7417 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7413 |
Intermediate Similarity |
NPD1357 |
Approved |
0.74 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7377 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7347 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7346 |
Intermediate Similarity |
NPD7028 |
Phase 2 |
0.7343 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.732 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7312 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7305 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7289 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7261 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7256 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7214 |
Intermediate Similarity |
NPD228 |
Approved |
0.7212 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7209 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7184 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7178 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7168 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD3657 |
Discovery |
0.7143 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7143 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7134 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7133 |
Intermediate Similarity |
NPD4624 |
Approved |
0.7126 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7126 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7123 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7123 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7123 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7118 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7115 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7095 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7071 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7071 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7071 |
Intermediate Similarity |
NPD3021 |
Approved |
0.707 |
Intermediate Similarity |
NPD6099 |
Approved |
0.707 |
Intermediate Similarity |
NPD6100 |
Approved |
0.707 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.707 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7067 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7063 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7048 |
Intermediate Similarity |
NPD3383 |
Approved |
0.7048 |
Intermediate Similarity |
NPD3384 |
Approved |
0.7048 |
Intermediate Similarity |
NPD3382 |
Approved |
0.7047 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7045 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7042 |
Intermediate Similarity |
NPD7635 |
Approved |
0.7037 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7037 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7037 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7035 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7035 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7035 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7029 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7025 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7025 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7019 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7019 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7018 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7014 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7006 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7006 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7006 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6989 |
Remote Similarity |
NPD7251 |
Discontinued |
0.6983 |
Remote Similarity |
NPD4663 |
Approved |
0.6982 |
Remote Similarity |
NPD4055 |
Discovery |
0.6982 |
Remote Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.6981 |
Remote Similarity |
NPD970 |
Clinical (unspecified phase) |
0.6975 |
Remote Similarity |
NPD1511 |
Approved |
0.6975 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6968 |
Remote Similarity |
NPD4140 |
Approved |
0.6964 |
Remote Similarity |
NPD3817 |
Phase 2 |
0.6948 |
Remote Similarity |
NPD5109 |
Approved |
0.6948 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6948 |
Remote Similarity |
NPD5111 |
Phase 2 |
0.6948 |
Remote Similarity |
NPD5110 |
Phase 2 |
0.6944 |
Remote Similarity |
NPD7906 |
Approved |
0.6937 |
Remote Similarity |
NPD5177 |
Phase 3 |
0.6933 |
Remote Similarity |
NPD5327 |
Phase 3 |
0.6933 |
Remote Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.6919 |
Remote Similarity |
NPD3051 |
Approved |
0.6918 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD1375 |
Discontinued |
0.6913 |
Remote Similarity |
NPD3092 |
Approved |
0.6913 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6913 |
Remote Similarity |
NPD1611 |
Approved |
0.691 |
Remote Similarity |
NPD4577 |
Approved |
0.691 |
Remote Similarity |
NPD4578 |
Approved |
0.6905 |
Remote Similarity |
NPD7819 |
Suspended |
0.6905 |
Remote Similarity |
NPD5929 |
Approved |
0.6897 |
Remote Similarity |
NPD709 |
Approved |
0.689 |
Remote Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.689 |
Remote Similarity |
NPD1512 |
Approved |
0.6887 |
Remote Similarity |
NPD1283 |
Approved |
0.6879 |
Remote Similarity |
NPD2969 |
Approved |
0.6879 |
Remote Similarity |
NPD6353 |
Approved |
0.6879 |
Remote Similarity |
NPD2970 |
Approved |
0.6875 |
Remote Similarity |
NPD7037 |
Approved |
0.6872 |
Remote Similarity |
NPD8053 |
Approved |
0.6872 |
Remote Similarity |
NPD8054 |
Approved |
0.6871 |
Remote Similarity |
NPD7040 |
Clinical (unspecified phase) |
0.6871 |
Remote Similarity |
NPD3091 |
Approved |
0.6871 |
Remote Similarity |
NPD7041 |
Phase 2 |
0.6867 |
Remote Similarity |
NPD7458 |
Discontinued |
0.686 |
Remote Similarity |
NPD8127 |
Discontinued |
0.686 |
Remote Similarity |
NPD6959 |
Discontinued |
0.6859 |
Remote Similarity |
NPD2238 |
Phase 2 |
0.6857 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6851 |
Remote Similarity |
NPD7243 |
Clinical (unspecified phase) |
0.6849 |
Remote Similarity |
NPD7340 |
Approved |
0.6839 |
Remote Similarity |
NPD2489 |
Approved |
0.6839 |
Remote Similarity |
NPD27 |
Approved |
0.6835 |
Remote Similarity |
NPD6111 |
Discontinued |
0.6829 |
Remote Similarity |
NPD7447 |
Phase 1 |
0.6829 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6829 |
Remote Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.6826 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6826 |
Remote Similarity |
NPD4675 |
Approved |
0.6826 |
Remote Similarity |
NPD4678 |
Approved |
0.6824 |
Remote Similarity |
NPD5691 |
Approved |
0.6818 |
Remote Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.6816 |
Remote Similarity |
NPD7311 |
Approved |
0.6816 |
Remote Similarity |
NPD7312 |
Approved |
0.6816 |
Remote Similarity |
NPD7313 |
Approved |
0.6816 |
Remote Similarity |
NPD7310 |
Approved |
0.6815 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6815 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6812 |
Remote Similarity |
NPD940 |
Approved |
0.6812 |
Remote Similarity |
NPD846 |
Approved |
0.6805 |
Remote Similarity |
NPD8455 |
Phase 2 |
0.6804 |
Remote Similarity |
NPD7827 |
Phase 1 |
0.6803 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6792 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.679 |
Remote Similarity |
NPD6331 |
Phase 2 |
0.679 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.679 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.679 |
Remote Similarity |
NPD7466 |
Approved |
0.6786 |
Remote Similarity |
NPD5089 |
Approved |
0.6786 |
Remote Similarity |
NPD5090 |
Approved |
0.6784 |
Remote Similarity |
NPD5604 |
Discontinued |
0.6784 |
Remote Similarity |
NPD7832 |
Clinical (unspecified phase) |
0.6784 |
Remote Similarity |
NPD7833 |
Phase 2 |
0.6784 |
Remote Similarity |
NPD7831 |
Phase 2 |
0.6778 |
Remote Similarity |
NPD7309 |
Approved |
0.6776 |
Remote Similarity |
NPD8651 |
Approved |
0.6774 |
Remote Similarity |
NPD7095 |
Approved |
0.6772 |
Remote Similarity |
NPD4579 |
Clinical (unspecified phase) |
0.6772 |
Remote Similarity |
NPD1607 |
Approved |
0.6768
|
Remote Similarity |
NPD7213 |
Phase 3 |